We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF (CONVERT-AF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01805960
Recruitment Status : Terminated
First Posted : March 6, 2013
Last Update Posted : February 14, 2017
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland

Brief Summary:
The purpose of this study is to test the efficacy of a single injection of Canakinumab on AF recurrences within 6 months after electrical cardioversion in patients with persistent AF.

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Biological: Canakinumab Biological: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Canakinumab for the Prevention of Recurrences After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation (CONVERT-AF) Trial - A Randomized Double Blind Placebo Controlled Study
Study Start Date : June 2013
Primary Completion Date : December 2016
Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Canakinumab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Canakinumab
1 s.c. injection of canakinumab 150mg directly after cardioversion
Biological: Canakinumab
Placebo Comparator: Placebo
1 s.c. injection directly after cardioversion
Biological: Placebo

Primary Outcome Measures :
  1. Recurrence of atrial fibrillation [ Time Frame: 180 days ]

Secondary Outcome Measures :
  1. Recurrence of atrial fibrillation [ Time Frame: 90 days ]
  2. Change in plasma levels of C-reactive protein [ Time Frame: 180 days ]
  3. Time to first redo cardioversion [ Time Frame: 180 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • EKG-documented AF
  • Undergoing electrical cardioversion
  • C-reactive protein ≥1.25mg/L
  • Age ≥ 50 years, women need to be postmenopausal

Exclusion Criteria:

  • Undergoing urgent cardioversion because of medical instability
  • AF persistence after cardioversion or AF recurrence before randomization
  • Atrial flutter
  • Severe renal failure (creatinine clearance <30 ml/min)
  • Known active or recurrent hepatic disorder (including cirrhosis, hepatitis A, B or C, or Alanine transaminase/aspartate aminotransferase levels >3x ULN or total bilirubin >2x ULN)
  • History of malignancy other than basal cell skin carcinoma
  • Known intolerance or allergic reactions to canakinumab
  • Use of amiodarone within the last 6 months
  • Known HIV or any other immune compromised state including neutropenia or immunodeficiency
  • History of ongoing, chronic or recurrent infectious disease
  • History or evidence of active tuberculosis (TB) infection at Visit 1 or one of the risk factors for tuberculosis such as but not limited or exclusive to:

    • History of any of the following: residence in a congregate setting (e.g. jail or prison, homeless shelter, or chronic care facility), substance abuse (e.g. injection or noninjection), health-care workers with unprotected exposure to patients who are at high risk of TB or patients with TB disease before the identification and correct airborne precautions of the patient.
    • Close contact (i.e. share the same air space in a household or other enclosed environment for a prolonged period (days or weeks, not minutes or hours)) with a person with active pulmonary TB disease within the last 12 months.
    • Evidence of tuberculosis infection, at Visit 1, determined as defined by local guidelines/ local medical practice (see also below for determination of tuberculosis status). If presence of tuberculosis is established then treatment (according to local guidelines) must have been completed prior to randomization. Completion of treatment is determined by local TB guidelines or in the absence of such guidelines the following has to be demonstrated: TB has been treated adequately with antibiotics, cure can be demonstrated, and risk factors resulting in TB exposure and contracting TB have been removed (e.g. the patient does not live anymore in high TB exposure setting).
  • Patients on systemic corticosteroids or other anti-inflammatory drugs other than non-steroidal anti-inflammatory drugs
  • Patients on any biological drug targeting the immune system
  • Acute coronary syndrome or acute stroke within 3 months
  • History of heart failure hospitalization within 3 months
  • Planned major surgery including planned coronary artery bypass grafting
  • Women of childbearing potential
  • Live vaccinations within 3 months prior to the randomization visit (visit 2) or live vaccinations planned during the trial.
  • Life expectancy <1 year
  • Inability to comply with the study protocol
  • Previously enrolled in CONVERT-AF
  • Patients who have received an investigational drug or device within 30 days of first visit.
  • History of alcohol and/or substance abuse that could interfere with the conduct of the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01805960

University Heart Center Hamburg
Hamburg, Germany
Department of Medicine, University Hospital
Basel, Switzerland, 4031
HUG Geneve
Geneve, Switzerland
CHUV Lausanne
Lausanne, Switzerland
Kantonsspital St. Gallen
St. Gallen, Switzerland
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Principal Investigator: David Conen, Prof. Cardiology, University Hospital Basel

Responsible Party: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT01805960     History of Changes
Other Study ID Numbers: CONVERT-AF Version5 22.01.2013
First Posted: March 6, 2013    Key Record Dates
Last Update Posted: February 14, 2017
Last Verified: February 2017

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Disease Attributes
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs